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Intrarenal angiotensin II: Interstitial and cellular levels and Uptake from the circulation has been demonstrated
site of production. in heart, adrenal and kidney [1–3]. In rat and porcine
Background. Both local production and angiotensin II sub- kidney, blood-derived Ang II is accumulated to levels (pertype 1 (AT1) receptor-mediated uptake from the circulation
gram tissue) several times the level (per mL) in bloodcontribute to the high levels of angiotensin (Ang) II in the
plasma [1–3]. This process depends on binding to cellkidney. It is largely unknown where Ang II is produced in the
kidney and how much of it originates from the circulation. membrane AT1 receptors, followed by receptor-medi-
Methods. The concentrations of endogenous and 125I-labeled ated endocytosis [1]. Cell-associated blood-derived Ang II
Ang I and II were measured in renal tissue and in blood from
has a longer half-life than Ang II in the circulation [1]pigs receiving systemic infusions of 125I-Ang I. Pigs were either
but the function of internalized Ang II is not known.untreated or treated with the angiotensin converting enzyme
(ACE) inhibitor captopril or the AT1 receptor antagonist epro- Chronic low-dose Ang II infusions in uninephrectom-
sartan. ized rats increased the level of Ang II in renal tissue
Results. 125I-Ang I was undetectable in renal tissue but the but not in heart and adrenal [2, 3]. This effect becamesteady-state concentrations of 125I-Ang II in cortical and medul-
apparent not earlier than after ten days and was pre-lary tissue were four and two times the concentration in arterial
blood plasma, respectively. The tissue concentrations of endog- vented by the Ang II subtype 1 (AT1) receptor antago-
enous Ang II were 100 and 60 times higher than in arterial nist, losartan. It was therefore proposed that the AT1
plasma. Eprosartan reduced 125I-Ang II accumulation by 90%, receptor-dependent increase in renal Ang II duringbut did not lower tissue Ang II. Captopril did not alter either
chronic Ang II infusion was caused not only by receptor-125I-Ang II accumulation or tissue Ang II.
mediated endocytosis of blood-derived Ang II, but alsoConclusions. The bulk of Ang II in the kidney is cell-associ-
ated. The high tissue/blood concentration ratio of endogenous by an enhancement of intrarenal Ang II formation [2, 3].
Ang II may depend on the same mechanism as demonstrated High concentrations of Ang II have been detected
for 125I-Ang II, that is, AT1 receptor-mediated binding to cells in renal interstitial fluid by some [4], but not all [5],and endocytosis. If so, the results indicate that most renal AT1
investigators. High concentrations of Ang II also havereceptors are exposed to locally generated Ang II rather than
Ang II from the circulation. We propose the existence of a low- been found in proximal tubular fluid [6, 7]. Measure-
Ang II vascular system-related interstitial compartment that is ments of renin in renal lymph indicated that renal inter-
separate from tubular fluid, where, according to micropuncture
stitial fluid contains renin in high concentrations [8, 9],studies, Ang II levels might be high.
and the interstitial fluid compartment is thought to be
the site of intrarenal Ang II production.
This concept needs some qualification, since in juxta-Intrarenal angiotensin II (Ang II) has important ef-
glomerular cells, renin, angiotensinogen and Ang I andfects on renal function and urinary sodium excretion and,
Ang II are co-localized in secretory granules [10–12].via these local actions, on blood pressure regulation. The
Ang I and probably also Ang II are co-secreted withpresence of Ang II in renal tissue depends on two mecha-
renin by these cells [10–12]. The detection of high levelsnisms: uptake from the circulation and local production.
of Ang II in renal interstitial fluid may be viewed as
evidence supporting the functional significance of locallyKey words: renin-angiotensin system, AT1 receptor, ACE inhibitor,
interstitium, blood pressure regulation, circulation. produced Ang II. This finding, however, is difficult to
reconcile with the fact that the kidney is very sensitiveReceived for publication January 29, 2001
to systemically infused Ang II [13].and in revised form June 28, 2001
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much is produced locally, and (2) to collect information of 125I-Ang I as described before [15]. Plasma was stored
at 70C and assayed within three days.on the site of intrarenal Ang II production and on its
Renal tissue samples were collected as follows. Thedistribution over the interstitial fluid and cell compart-
heart was stopped by fibrillation while the 125I-Ang Iments. Our approach was to measure the concentrations
infusion was still running. The abdomen was opened byof endogenous Ang I and II in conjunction with measure-
a longitudinal incision and both kidneys were rapidlyments of 125I-Ang I and II in renal cortical and medullary
dissected. Pieces of renal cortex and medulla (1 to 2 g)tissue from pigs receiving a systemic infusion of 125I-
were immediately frozen in liquid nitrogen and storedAng I. Studies were performed in untreated animals and
at 70C.after treatment with an ACE inhibitor or AT1 receptor
antagonist. The rationale for using these drugs as investi- Measurement of angiotensins
gative tools lies in the fact that they act at different
125I-labeled and endogenous Ang I and Ang II werelevels of the renin-angiotensin system, and may therefore
measured as described previously [1, 16, 17], using Sep-differentially affect the uptake, production and compart-
Pak extraction and high-performance liquid chroma-mentalization of Ang II in the kidney.
tography (HPLC) separation. The concentrations of 125I-
labeled and endogenous angiotensins were not corrected
for losses occurring during extraction and separationMETHODS
(20 to 30% in whole tissue homogenates and 10% inAnimals
plasma [1, 16, 17]). For Ang I, the lower limit of detection
All experiments were carried out under the regula- was 0.5 fmol/mL of plasma and 1 fmol/g of tissue. For
tions of the Animal Care Committee of the Erasmus Ang II, the lower limit of detection was 0.3 fmol/mL of
University Rotterdam, Rotterdam, The Netherlands, in plasma and 0.5 fmol/g of tissue.
accordance with the Guide for the Care and Use of Labo-
Calculationsratory Animals as published by the U.S. National Insti-
tutes of Health. Twenty-one two- to three-month-old In a previous study [1] we observed that the renal
Yorkshire Landrace pigs (weight 25 to 30 kg) of either tissue/arterial plasma concentration ratio of 125I-Ang II
during 125I-Ang I infusion was not higher than duringsex were included in the study. In all animals a suture
125I-Ang II infusion. Thus, the 125I-Ang II that was presentwas placed around the left circumflex coronary artery
in renal tissue was derived from arterially delivered(LCXCA) in order to examine the effect of coronary
125I-Ang II and not, via conversion, from arterially deliv-ligation on the cardiac levels of Ang II in these animals
ered 125I-Ang I. The renal tissue level of Ang II (fmol/g)[14]. The LCXCA was permanently ligated in 16 animals,
that originates from angiotensin in the circulation waswhereas the suture was removed in five animals (sham
therefore calculated as follows:operation). Of the permanently ligated animals, five re-
ceived captopril (25 mg b.i.d.), and five animals received [Ang IItissue] originating from circulation
the AT1 receptor antagonist eprosartan (400 mg b.i.d.;
 R  [Ang IIart] (Eq. 1)a kind gift of Dr. P.K. Weck, SmithKline Beecham, Col-
in which [Ang IIart] is the steady-state concentration oflegeville, PA, USA). This dose of eprosartan blocks
Ang II in arterial plasma (fmol/mL), and R is definedAng II-induced pressor responses by 95% [14]. Treat-
by the equation:ment was started 12 to 24 hours after ligation and was
continued for three weeks. R  [125I-Ang IItissue]/[125I-Ang IIart] (Eq. 2)
in which [125I-Ang IItissue] and [125I-Ang IIplasma] are theInstrumentation and 125I-angiotensin infusion
steady-state concentrations of 125I-Ang II in tissueThree weeks after ligation or sham operation, animals
(cpm/g) and arterial plasma (cpm/mL), respectively.were prepared for administration of anesthetic and 125I-
Ang I and for blood and tissue sampling as described Data analysis
previously [1]. After a stabilization period of 30 to 45 Data are expressed as mean  SEM. Differences be-
minutes following completion of instrumentation, ani- tween treated and untreated animals were tested by
mals were subjected to a one-hour infusion of 125I-Ang I ANOVA. Statistical significance was accepted at P 0.05.
(1.5  106 cpm/min) into the left ventricle. 125I-Ang I
and II reach steady-state levels in plasma within ten
RESULTSminutes, and in renal tissue within 60 minutes [1, 15].
Uptake of angiotensin II from blood versus
Collection of blood and tissue samples local production and contribution to tissue
angiotensin II levelsTo measure the plasma levels of 125I-labeled and en-
dogenous Ang I and II, blood samples (5 to 10 mL) were Figure 1 shows an example of high pressure liquid chro-
matography (HPLC) separation patterns of 125I-labeledtaken from the aorta and a renal vein during the infusion
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Fig. 2. Levels of endogenous angiotensin I in renal tissue and blood
plasma in 11 control, 5 captopril-treated and 5 eprosartan-treated pigs.
Medullary tissue and venous blood were not available in 4 of the 11
control animals. Data are mean  SEM. *P  0.05 for difference from
control.
Fig. 1. High-performance liquid chromatography (HPLC) elution pro-
file of 125I-labeled and endogenous angiotensins in renal cortical tissue
measured by gamma counting and radioimmunoassay, respectively.
Samples were obtained from a control pig (A), a captopril-treated pig Fig. 3. Levels of endogenous angiotensin II in renal tissue and blood
(B), and an eprosartan-treated pig (C ) following a one-hour infusion plasma in 11 control, 5 captopril-treated and 5 eprosartan-treated pigs.
of 125I-angiotensin I. Retention times of 125I-labeled standards are indi- Medullary tissue and venous blood were not available in 4 of the 11
cated at the top. 1, 125I-tyrosine; 2, 125I-angiotensin-(1-7); 3, 125I-angioten- control animals. The black area represents the amount of angiotensin
sin(4-8); 4, 125I-angiotensin II; 5, 125I-angiotensin I. Bars represent endog- II that is plasma-derived. Data are mean  SEM. *P  0.05 for differ-
enous angiotensin (Ang) I and II. ence from control.
affect plasma angiotensin levels [14]. Ligation also didand endogenous angiotensins in renal tissue from un-
not affect renal angiotensin levels. Ang I and II concen-treated animals and animals treated with captopril or
trations in renal cortex were 53.8  9.6 and 109  39.2eprosartan. The levels of endogenous Ang I and II in
fmol/g in permanently ligated animals (N 6) and 68.4arterial and renal venous blood plasma and in renal corti-
24.6 and 115  10.4 fmol/g in sham-operated animalscal and medullary tissue are shown in Figures 2 and 3.
(N  5). Data for the two groups were therefore com-In control animals (that is, animals that were not treated
with captopril or eprosartan), coronary ligation did not bined. In the combined control group, the levels of en-
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Table 2. Renal tissue/arterial blood plasma concentration ratios andTable 1. Renal tissue/arterial blood plasma concentration ratios and
renal venous/arterial blood plasma concentration ratios of renal venous/arterial blood plasma concentration ratios of
125I-angiotensin II and endogenous angiotensin II125I-angiotensin I and endogenous angiotensin I
Control Captopril Eprosartan Control Captopril Eprosartan
(N11) (N5) (N5)(N11) (N5) (N5)
125I-angiotensin I 125I-angiotensin II
Cortex/artery 4.10.6 4.70.6 0.380.06aCortex/artery 0 0 0
Medulla/artery 0 0 0 Medulla/artery 1.80.2b 1.50.1b 0.230.06ab
Vein/artery 0.120.02 0.180.07 0.090.01Vein/artery 0.150.05 0.140.04 0.070.02
Endogenous angiotensin I Endogenous angiotensin II
Cortex/artery 10230 81.332.0 23.45.3aCortex/artery 20.65.4 4.91.1a 14.84.9
Medulla/artery 43.310.5 5.51.7a 7.11.0a Medulla/artery 64.414.4 64.919.4 14.94.9a
Vein/artery 0.4c 0.600.24 0.150.03Vein/artery 0.910.23 0.780.18 1.10.3
Steady-state levels of 125I-angiotensin II in arterial plasma ranged from 161 toSteady-state levels of 125I-angiotensin I in arterial plasma ranged from 308 to
519 cpm/mL in the untreated animals, and from 448 to 828 cpm/mL and 359 to 793 530 cpm/mL in the untreated animals, and from 49 to 158 cpm/mL and 323 to
405 cpm/mL in the captopril-treated and eprosartan-treated animals, respec-cpm/mL in the captopril-treated and eprosartan-treated animals, respectively.
Medullary tissue and venous blood were not available in 4 of the 11 control tively. Medullary tissue and venous blood were not available in 4 of the 11
control animals. Data are mean  SEM.animals. Data are mean  SEM.
a P  0.05 for difference from control a P  0.05 vs. control
b P  0.05 vs. cortex/artery ratio
c Endogenous Ang II was not detectable (0.3 fmol/mL) in renal venous
plasma from 5 animals
dogenous Ang I in cortical and medullary tissue were
similar (Fig. 2), and the same applies to the levels of
endogenous Ang II at these sites (Fig. 3). in arterial plasma also was lower in the captopril-treated
animals than in controls (0.17  0.04 vs. 0.54  0.08;125I-Ang I was not detectable in tissue (Fig. 1). In con-
trast, the tissue concentration of endogenous Ang I was P  0.01). 125I-Ang I was undetectable in tissue after
captopril, as was the case in controls.much higher than the concentration in arterial plasma
(Table 1). Thus, virtually all tissue Ang I appears to The Ang II/I concentration ratios in cortical tissue
were not significantly different in captopril-treated ani-originate from local production in the kidney.
The concentration of 125I-Ang II in cortical tissue was mals and controls (1.80  0.19 and 2.27  0.47, respec-
tively). This was also true for the Ang II/I concentrationfour times the concentration in arterial plasma, and the
cortical tissue concentration of endogenous Ang II was ratios in medullary tissue (1.29  0.18 and 2.00  0.66,
respectively). In the captopril group, as in controls, most100 times the concentration in arterial plasma (Table 2).
The 125I-Ang II concentration in medullary tissue was tissue Ang II appears to be derived from local produc-
tion, and not from the circulation (Fig. 3).two times the concentration in arterial plasma, and en-
dogenous Ang II in medullary tissue was 60 times higher The 125I-Ang II/I concentration ratio in arterial plasma
was 0.73  0.09 in the eprosartan-treated animals (N than in arterial plasma. Thus, the tissue/blood plasma
5), which was not different from the ratio in controls.concentration ratio was much higher for endogenous
The endogenous Ang II/I concentration ratio in arterialAng II than it was for 125I-Ang II. These results show
plasma in the eprosartan-treated animals was 0.92 0.09,that about 85% of tissue Ang II originated from local
which was also not different from the ratio in controls.production by the kidney (Fig. 3).
125I-Ang I was undetectable both in cortical and medul-Only 10 to 15% of arterially delivered 125I-Ang I
lary tissue in the eprosartan-treated animals, as was thereached the renal vein, and the same was true for
case in the captopril group and in controls. In the epro-125I-Ang II (Tables 1 and 2). The concentration of endog-
sartan group, as in the captopril group and in controls,enous Ang I in renal venous plasma was not different
most tissue Ang II appears to be derived from localfrom that in arterial plasma (Table 1). Therefore, it ap-
production and not from the circulation (Fig. 3).pears that 85 to 90% of renal venous Ang I originates
In the captopril group, the cortical tissue concentrationfrom production within the kidney. No such release from
of 125I-Ang II was about five times the concentration in ar-renal tissue sites could be demonstrated for Ang II, since
terial plasma, which was not significantly different fromthe renal venous/arterial plasma concentration ratio of
the cortical tissue/arterial plasma 125I-Ang II concentra-endogenous Ang II was as low as that of 125I-Ang II
tion ratio in controls (Table 2). In the eprosartan group,(Table 2).
the cortical tissue concentration of 125I-Ang II was only
Effects of captopril and eprosartan 0.4 times the concentration in arterial plasma. A similar
difference between the eprosartan group on the oneCaptopril lowered the 125I-Ang II/I ratio in arterial
plasma. It was 0.17  0.03 (N  5) in the captopril- hand and the captopril and control groups on the other
was seen for the medullary tissue concentrations of 125I-treated animals, as compared to 0.53  0.05 (N  11)
in controls (P  0.01). The endogenous Ang II/I ratio Ang II. These results demonstrate that the accumulation
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of blood-derived Ang II in tissue is mediated by AT1 conclusion that the bulk of Ang II in the kidney is formed
locally by conversion of locally produced Ang I and isreceptors.
The renal venous/arterial plasma concentration ratios not derived from Ang I or II in the circulation.
Our results provide some information on the distribu-of both 125I-Ang I and 125I-Ang II in the animals treated
with captopril and eprosartan were comparable to the tion of Ang II in the extracellular and cell compartments
of renal tissue. In this context, one has to consider theratios in controls, and the same was true for endogenous
Ang I (Tables 1 and 2). The renal venous/arterial plasma possibility that blood-derived Ang II does not enter all
regions of the kidney. For the sake of simplicity, weconcentration ratio of endogenous Ang II in the capto-
pril group tended to be higher than in the other groups, consider a region that is reached by blood-derived Ang II
and a region that is not reached by blood-derived Ang II.but the difference did not reach statistical significance.
Our results in the captopril and eprosartan groups were The present study showed a 90% reduction of the tissue/
arterial plasma 125I-Ang II concentration ratio after epro-therefore similar to those in controls, in that these results
provided evidence for the release of Ang I, but not sartan. If it is assumed that after the AT1 receptors had
been blocked by eprosartan, all 125I-Ang II in tissue wasAng II, from renal tissue into the circulation.
localized in extracellular fluid, our results would imply
that, in the absence of AT1 receptor blockade, 10% ofDISCUSSION 125I-Ang II in the kidney, in the region in which blood-
Intrarenal Ang II has important functions in regulating derived Ang II is distributed, is localized in extracellular
urine flow, urinary sodium excretion and glomerular fil- fluid and 90% is cell-associated. Most likely, however,
tration rate. It has a major role in the pathogenesis of AT1 receptor blockade by eprosartan was not complete.
2-kidney, 1 clip (2K1C) hypertension and possibly also If our finding that the tissue/arterial plasma 125I-Ang II
in the hypertension of the spontaneously hypertensive concentration ratio was reduced by 90% after eprosartan
rat [2, 3, 18, 19]. Although renin is suppressed in the would be the consequence of 90% AT1 receptor occu-
contralateral non-clipped kidney of 2K1C hypertensive pancy by this drug, then 100% occupancy would result
rats and in the remaining kidney of uninephrectomized in a tissue/arterial plasma 125I-Ang II concentration ratio
rats during chronic low dose Ang II infusion, Ang II in of zero, which would mean that, in the absence of AT1
the kidneys is increased to levels that are too high to be receptor blockade, virtually all 125I-Ang II in the kidney
explained by passive diffusion from circulation to tissue is cell-associated.
[18]. Studies using AT1 receptor antagonists provided That AT1 receptor blockade after eprosartan was in-
strong evidence to support that tissue Ang II in the deed not complete, was indicated by earlier experiments
non-clipped kidney contributes to the pathogenesis of in which we measured the steady-state levels of 125I-
systemic hypertension by reducing renal function and Ang II in subcellular fractions of renal cortical tissue
sodium excretion [19]. AT1 receptor-mediated uptake from pigs receiving systemic infusions of 125I-Ang I or II
and accumulation of Ang II from the circulation could [20]. Not only in control animals, but also in animals
be one of the mechanisms by which intrarenal Ang II is treated with the same doses of eprosartan as used in the
maintained even when renin is suppressed [1–3]. An- present study, 125I-Ang II was found to be concentrated
other possibility is the existence of a positive feedback in the nuclear, lysosomal and microsomal cell fractions.
loop by which intrarenal Ang II formation is enhanced In the eprosartan-treated animals, 70% of the total
after AT1 receptor stimulation [2, 3]. amount of 125I-Ang II in the combined cell fractions was
The present study in pigs shows that, normally, most found in the nuclear, lysosomal and microsomal fractions
Ang II in the kidney is not derived from the circulation, with less than 20% loss of 125I-Ang II during preparation
but is produced locally. We found that AT1 receptor- of these fractions. These results indicate that AT1 recep-
mediated binding and accumulation of 125I-Ang II from tor blockade was not complete and that indeed nearly
the circulation led to a tissue level four times the level all blood-derived Ang II in renal cortical tissue is cell-
in arterial plasma, whereas the tissue level of endogenous associated.
Ang II was 100 times the level in arterial plasma. It is commonly held that tissue Ang II is produced in
125I-Ang I from the circulation was not accumulated. Its the extracellular interstitial fluid compartment. Extracel-
tissue level was at or below the detection limit, whereas lular Ang II is then bound to cell surface AT1 receptors
endogenous Ang I in tissue was much higher than in and internalized. If this view is correct, our results imply
arterial plasma. A previous study, in which we compared that most renal AT1 receptors are exposed to locally
the results after 125I-Ang I infusion with those after produced Ang II rather than Ang II from the circulation.
125I-Ang II infusion, has shown that the 125I-Ang II that Following this line of reasoning, we propose that the high
was found in renal tissue was derived from arterially tissue/arterial plasma concentration ratio of endogenous
delivered 125I-Ang II and not from arterially delivered Ang II, as observed in the present study, depends on
the same mechanism as has been demonstrated for 125I-125I-Ang I [1]. Taken together, our results lead to the
van Kats et al: Intrarenal angiotensin II2316
Ang II, that is, AT1 receptor-mediated binding to cells not decreased by this drug. Thus, neither the decrease
in AT1 receptor-mediated uptake nor a negative effectfollowed by internalization. The concept that receptor-
mediated binding and endocytosis are instrumental in on intrarenal Ang II formation caused by interruption of
a supposedly positive AT1 receptor-dependent feedbackmaintaining a low Ang II concentration in interstitial
fluid also is supported by our finding that 85 to 90% of loop [2, 3] had led to a decrease in tissue Ang II after
Ang I in renal venous plasma had been produced within eprosartan administration. This might be explained, at
the kidney, whereas no significant release of Ang II from least in part, by the stimulation of renin following AT1
the kidney into the circulation could be demonstrated. receptor blockade. Such stimulation causes enhanced
Similar observations were made in humans [21, 22]. Ang II generation in extracellular fluid, as reflected by
This concept, however, seems to be at variance with increased plasma Ang II (Fig. 3). The decrease in the
a study in which Ang II was measured in renal interstitial tissue/arterial plasma concentration ratio of endogenous
fluid from rats using a microdialysis technique [4]. In Ang II after eprosartan was similar to the decrease in the
that study the Ang II concentration in interstitial fluid tissue/arterial plasma concentration ratio of 125I-Ang II
was found to be 1000 to 10,000 times the concentration (Table 2), which is in agreement with the concept that
in plasma. How can this discrepancy be explained? Siragy endogenous Ang II, like 125I-Ang II, enters the cells via
et al measured so-called immunoreactive Ang II-like AT1 receptor-mediated endocytosis. However, because
material [4], whereas we measured HPLC-purified Ang of the eprosartan-induced rise in extracellular Ang II,
II. However, it is unlikely that this is sufficient explana- the kidney is capable of maintaining its high intracellular
tion. A more fundamental problem could be the microdi- Ang II levels despite the AT1 receptor blockade. An
alysis technique itself. In order to perform microdialysis additional explanation for the absence of eprosartan-
experiments, a dialysis membrane probe has to be in- induced reductions in renal Ang II could be that changes
serted into the tissue. The probe used by Siragy et al in Ang II concentration in whole tissue do not reliably
had an internal diameter of 0.3 mm [4]. The presence of reflect the changes that might occur at the level of AT1
this probe alters the micro-environment of the sur- receptors in the tissue region in which blood-derived
rounding cells. Normally, the water space between the Ang II is distributed. In our study renal tissue Ang II also
cells is very small. Considering a model of two parallel was not reduced by treatment with the ACE inhibitor
cell layers 1 m apart, insertion of a cylindrical probe captopril in doses that were high enough to suppress the
of 0.3 mm diameter between the two layers will increase Ang II/I concentration ratio in blood. It is tempting to
the extracellular space separating the cells by a factor invoke alternative pathways of Ang I-II conversion.
of about 150 (cross-sectional area of cylinder divided by Other explanations however, like those mentioned above
the product of half cylinder circumference and normal with respect to the effects of eprosartan, cannot be ex-
distance between cell layers). As a consequence, the cell cluded.
surface receptors facing the probe are bathed in a much Micropuncture experiments showed high levels of
larger volume of water than normal. The binding of Ang II in proximal tubular fluid from rats [6, 7]. There
Ang II to its receptors, therefore, takes place at an artifi- is further evidence in the rat that interstitial cells, located
cially low receptor concentration. If normally the in vivo in the inner stripe of the outer renal medulla, are exposed
binding of Ang II takes place at receptor concentrations to high interstitial Ang II concentrations [23, 24]. When
that are higher than the equilibrium dissociation constant these observations are incorporated into our results, a
(Kd), so that most Ang II is complexed with the receptors, picture emerges in which the renal interstitium contains
a 150-fold reduction in receptor density may lead to a a low-Ang II vascular system-related compartment, and
new steady state with a big increase in free Ang II. It is a high-Ang II tubular system-related compartment. The
therefore possible that the high Ang II level, as measured juxtaglomerular cells, as part of the vascular compart-
with the microdialysis technique, is an artifact. ment, are in close anatomical relationship with the mac-
Our proposal that the high AT1 receptor density in ula densa cells that are part of the tubular compartment.
the kidney is responsible for a low Ang II concentration These cells are therefore strategically situated to serve
in interstitial fluid has important implications. It means communication between the two compartments.
there is no need for postulating a blood/interstitium ‘bar-
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